Search results for " Mab"
Article
Scaling a mAb production process to Xcellerex bioreactors
Moving a monoclonal antibody production process from a microscale bioreactor to the Xcellerex XDR single-use platform.
READ MORE >>
Article
A Small-Scale Model to Increase Yield in Cell Culture Perfusion of mAbs at Large Scale
Read full article>>
As process intensification is adopted into large-scale manufacturing, the responsibility on scale-down models to accurately represent the expanded operating space quic…
Resource
Strategies and Emerging Technologies for mAb Capture
20 May 17 CEST | 11 EDT
Article
A Small-Scale Model to Increase Yield in Cell Culture Perfusion of mAb at Large Scale
Click here to read more >>
As process intensification is adopted into large-scale manufacturing, the responsibility on scale-down models to accurately represent the expanded operating space quick…
Article
Connected, Automated Downstream Process for mAb Screening and Evaluation
Click here to read more >>
A pre-clinical lab is often faced with the need to constantly evaluate possible ways of increasing capacity and throughput. This study was done to show both proof of p…
Article
Monoclonal Antibodies Key to Unlocking the Biosimilars Market
The European Medicines Agency (EMA) approved the first mAb biosimilar developed by Celltrion and Hospira in 2013 (infliximab: Remsima/Inflectra). Development of clear, regulatory approval pathways for…
Article
Evolution of the Monoclonal Antibody Purification Platform
What is unique about mAbs from a processing perspective is the applicability of developing a common process and analytical platform (2, 3). Some process development related attributes with respect to …
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Increasing upstream titers and shrinking development timelines have posed several challenges to downstream process development of mAbs. Some of the major strategies and tools to address these challeng…
Article
Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products
“This characterization should include the determination of physicochemical and immunochemical properties, biological activity, purity, impurities, and quantity of the mAb, in line with ICH Q6B guideli…
Article
HT Multi-Product Liquid Chromatography for Characterization of Monoclonal Antibodies
REGULATORY EXPECTATIONS FOR THE ANALYSIS OF MABS
Several guidance documents have been issued by regulatory agencies recommending approaches for protein characterization.3,4 Although guidance docum…